Indeed, it was found that the mutated p53 tunes Nrf2-dependent antioxidant response, promoting tumor cell survival, and the p53-Nrf2 axis upregulates the proteasome machinery, conferring resistance to proteasome inhibitors used in cancer therapy. The gene discussed is TP53; the disease is neoplasm.